Potential Targets of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for Multiple Sclerosis Therapy

Journal of Immunology

Volumn 172, Issue 2, 2004, Pages 1273-1286

  Nath, Narender ^a   Giri, Shailendra ^a   Prasad, Ratna ^a   Singh, Avtar K ^b   Singh, Inderjit ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE 2; MEVINOLIN; PROTEIN TYROSINE KINASE; STAT4 PROTEIN; STAT6 PROTEIN; T BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR ALPHA; TYROSINE KINASE 2; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; FEMALE; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; TH2 CELL;

EID: 1642454666     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.2.1273     Document Type: Article

References (65)

1. Ozawa, K., G. Suchanek, H. Breitschopf, W. Bruck, H. Budka, K. Jellinger, and H. Lassmann. 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311.
2. Lassmann, H., C. S. Raine, J. Antel, and J. W. Prineas. 1998. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J. Neuroimmunol. 86:213.
3. Lucchinetti, C. F., W. Bruck, M. Rodriguez, and H. Lassmann. 1996. Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis. Brain Pathol. 6:259.
4. Weiner, H. L., and D. J. Selkoe. 2002. Inflammation and therapeutic vaccination in CNS diseases. Nature 420:879.
5. Swanborg, R. H. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77:4.
6. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:5.
7. Frei, K., H. P. Eugster, M. Bopst, C. S. Constantinescu, E. Lavi, and A. Fontana. 1997. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:2177.
8. Lublin, F. D., R. L. Knobler, B. Kalman, M. Goldhaber, J. Marini, M. Perrault, C. D'Imperio, J. Joseph, S. S. Alkan, and R. Korngold. 1993. Monoclonal antigamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16:267.
9. Liu, J., M. W. Marino, G. Wong, D. Grail, A. Dunn, J. Bettadapura, A. J. Slavin, L. Old, and C. C. Bernard. 1998. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4:78.
10. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1193.
11. Korner, H., F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick. 1997. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system. Eur. J. Immunol. 27:1973.
12. Young, D. A., L. D. Lowe, S. S. Booth, M. J. Whitters, L. Nicholson, V. K. Kuchroo, and M. Collins. 2000. IL-4, IL-10, IL-13, and TGF-β from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 164:3563.
13. Croxford, J. L., M. Feldmann, Y. Chernajovsky, and D. Baker. 2001. Different therapeutic outcomes in experimental allergic encephalomyelitis dependent upon the mode of delivery of IL-10: a comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system. J. Immunol. 166:4124.
14. Santambrogio, L., G. M. Hochwald, B. Saxena, C. H. Leu, J. E. Martz, J. A. Carlino, N. H. Ruddle, M. A. Palladino, L. I. Gold, and G. J. Thorbecke. 1993. Studies on the mechanisms by which transforming growth factor-β (TGF-β) protects against allergic encephalomyelitis: antagonism between TGF-β and tumor necrosis factor. J. Immunol. 151:1116.
15. Legge, K. L., B. Min, J. J. Bell, J. C. Caprio, L. Li, R. K. Gregg, and H. Zaghouani. 2000. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J. Exp. Med. 191:2039.
16. Ando, D. G., J. Clayton, D. Kono, J. L. Urban, and E. E. Sercarz. 1989. Encephalitogenic T cells in the B10. PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124:132.
17. Zamvil, S., P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. Fritz, and L. Steinman. 1985. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 317:355.
18. Zamvil, S. S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:579.
19. Laufs, U., K. Gertz, U. Dirnagl, M. Bohm, G. Nickenig, and M. Endres. 2002. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 942:23.
20. Zamvil, S. S., and L. Steinman. 2002. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 59:970.
21. Weitz-Schmidt, G. 2002. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23:482.
22. Sadeghi, M. M., M. Collinge, R. Pardi, and J. R. Bender. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165:2712.
23. Kobashigawa, J. A., S. Katznelson, H. Laks, J. A. Johnson, L. Yeatman, X. M. Wang, D. Chia, P. I. Terasaki, A. Sabad, G. A. Cogert, et al. 1995. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333: 621.
24. Dimitroulakos, J., L. Y. Ye, M. Benzaquen, M. J. Moore, S. Kamel-Reid, M. H. Freedman, H. Yeger, and L. Z. Penn. 2001. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin. Cancer Res. 7:158.
25. Mueck, A. O., H. Seeger, and D. Wallwiener. 2001. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp. Clin. Endocrinol. Diabetes 109:181.
26. Denoyelle, C., P. Albanese, G. Uzan, L. Hong, J. P. Vannier, J. Soria, and C. Soria. 2003. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell. Signalling 15:327.
27. Leung, B. P., N. Sattar, A. Crilly, M. Prach, D. W. McCarey, H. Payne, R. Madhok, C. Campbell, J. A. Gracie, F. Y. Liew, et al. 2003. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 170:1524.
28. Feleszko, W., I. Mlynarczuk, E. Z. Balkowiec-Iskra, A. Czajka, T. Switaj, T. Stoklosa, A. Giermasz, and M. Jakobisiak. 2000. Lovastatin potentiates anti-tumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. 6:2044.
29. Pahan, K., F. G. Sheikh, A. M. Namboodiri, and I. Singh. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100:2671.
30. Stanislaus, R., K. Pahan, A. K. Singh, and I. Singh. 1999. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269:71.
31. Stanislaus, R., A. K. Singh, and I. Singh. 2001. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66:155.
32. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:1399.
33. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687.
34. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, et al. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78.
35. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655.
36. Zheng, W., and R. A. Flavell. 1997. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587.
37. Tompkins, S. M., J. Padilla, M. C. Dal Canto, J. P. Ting, L. Van Kaer, and S. D. Miller. 2002. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168:4173.
38. Howard, L. M., and S. D. Miller. 2001. Autoimmune intervention by CD154 blockade prevents T cell retention and effector function in the target organ. J. Immunol. 166:1547.
39. Weigel, B. J., N. Nath, P. A. Taylor, A. Panoskaltsis-Mortari, W. Chen, A. M. Krieg, K. Brasel, and B. R. Blazar. 2002. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. Blood 100:4169.
40. Giri, S., M. Jatana, R. Rattan, J. S. Won, I. Singh, and A. K. Singh. 2002. Galactosylsphingosine (psychosine)-induced expression of cytokine-mediated inducible nitric oxide synthases via AP-1 and C/EBP: implications for Krabbe disease. FASEB J. 16:661.
41. Bright, J. J., L. D. Kerr, and S. Sriram. 1997. TGF-β inhibits IL-2-induced tyrosine phosphorylation and activation of Jak 1 and Stat 5 in T lymphocytes. J. Immunol. 159:175.
42. Ouyang, W., M. Lohning, Z. Gao, M. Assenmacher, S. Ranganath, A. Radbruch, and K. M. Murphy. 2000. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 12:27.
43. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, and L. H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295:338.
44. Thierfelder, W. E., J. M. van Deursen, K. Yamamoto, R. A. Tripp, S. R. Sarawar, R. T. Carson, M. Y. Sangster, D. A. Vignali, P. C. Doherty, G. C. Grosveld, et al. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171.
45. Hilliard, B., E. B. Samoilova, T. S. Liu, A. Rostami, and Y. Chen. 1999. Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: roles of NF-κB in the activation and differentiation of autoreactive T cells. J. Immunol. 163:2937.
46. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2:725.
47. Karin, M., and Y. Ben-Neriah. 2000. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18:621.
48. Fischer, H. G., and G. Reichmann. 2001. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 166:2717.
49. + T cell priming and Th1/Th2 cell restimulation. Eur. J. Immunol. 29:2705.
50. Stanislaus, R., A. G. Gilg, A. K. Singh, and I. Singh. 2002. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci. Lett. 333:167.
51. Romano, M., L. Diomede, M. Sironi, L. Massimiliano, M. Sottocomo, N. Polentarutti, A. Guglielmotti, D. Albani, A. Bruno, P. Fruscella, et al. 2000. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 80:1095.
52. Finotto, S., M. F. Neurath, J. N. Glickman, S. Qin, H. A. Lehr, F. H. Green, K. Ackerman, K. Haley, P. R. Galle, S. J. Szabo, et al. 2002. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 295:336.
53. Mullen, A. C., F. A. High, A. S. Hutchins, H. W. Lee, A. V. Villarino, D. M. Livingston, A. L. Kung, N. Cereb, T. P. Yao, S. Y. Yang, et al. 2001. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 292:1907.
54. Pernis, A. B., and P. B. Rothman. 2002. JAK-STAT signaling in asthma. J. Clin. Invest. 109:1279.
55. Ohashi, P. S. 2002. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat. Rev. Immunol. 2:427.
56. Jacobson, N. G., S. J. Szabo, R. M. Weber-Nordt, Z. Zhong, R. D. Schreiber, J. E. Darnell, Jr., and K. M. Murphy. 1995. Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4. J. Exp. Med. 181:1755.
57. Kaplan, M. H., Y. L. Sun, T. Hoey, and M. J. Grusby. 1996. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174.
58. Chitnis, T., N. Najafian, C. Benou, A. D. Salama, M. J. Grusby, M. H. Sayegh, and S. J. Khoury. 2001. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 108:739.
59. Finkelman, F. D., S. C. Morris, T. Orekhova, M. Mori, D. Donaldson, S. L. Reiner, N. L. Reilly, L. Schopf, and J. F. Urban, Jr. 2000. Stat6 regulation of in vivo IL-4 responses. J. Immunol. 164:2303.
60. + lymphocytes with a Th2 cytokine profile. J. Immunol. 164:3047.
61. Ho, I. C., and L. H. Glimcher. 2002. Transcription: tantalizing times for T cells. Cell 109(Suppl.):S109.
62. Barnes, P. J., and M. Karin. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1066.
63. Beg, A. A., and D. Baltimore. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782.
64. Ting, A. T., F. X. Pimentel-Muinos, and B. Seed. 1996. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J. 15:6189.
65. Hilliard, B. A., N. Mason, L. Xu, J. Sun, S. E. Lamhamedi-Cherradi, H. C. Liou, C. Hunter, and Y. H. Chen. 2002. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 110:843.